患者与医生关于恶性肿瘤高钙血症治疗决策因素的混合方法研究
本研究采用混合方法,通过系统评价5个数据库、收集多国费用数据、临床实践指南工作组及患者的结果优先排序与问卷,评估患者和医生对恶性肿瘤高钙血症治疗的价值观、偏好与态度,为指南制定提供情境信息。系统评价纳入2项横断面调查和2项费用研究;工作组与患者均认为生存和纠正高钙血症是最重要结局。
要点
- 系统评价纳入2项针对同一医生群体的横断面调查,医生同意治疗恶性肿瘤高钙血症可缓解症状并改善生活质量。
- 费用研究显示静脉双膦酸盐比静脉双膦酸盐联合降钙素更具成本效益,家庭给予静脉唑来膦酸比其他静脉双膦酸盐更具成本效益。
- 临床实践指南工作组与患者均认为决策治疗时最重要的结局是生存和纠正高钙血症,其他结局评分存在差异。
核心结论
- 采用混合方法可使指南制定者获得关于证据至决策标准的 meaningful 信息,为恶性肿瘤高钙血症指南提供所需的情境信息并支持制定循证推荐。
研究设计与样本
- 混合方法研究:系统评价5个数据库,收集多国多种治疗方式费用数据,并收集临床实践指南工作组及恶性肿瘤高钙血症患者的结果优先排序与问卷数据。
主要发现
- 系统评价纳入2项针对同一医生群体的横断面调查,医生同意治疗恶性肿瘤高钙血症可缓解症状并改善生活质量,但决定治疗时长时应充分考虑 harms 与获益。
- 纳入2项费用研究:静脉双膦酸盐比静脉双膦酸盐联合降钙素更具成本效益;家庭给予静脉唑来膦酸比其他静脉双膦酸盐更具成本效益。
- 唑来膦酸、地舒单抗和西那卡塞的费用在不同国家及品牌与仿制类型间差异很大。
- 临床实践指南工作组与患者均认为决策治疗时最重要的结局是生存和纠正高钙血症,但其他结局的评分存在一定差异。
关键数值与推荐
- 系统评价纳入2项横断面调查和2项费用研究,共涉及医生价值观、治疗费用与成本效益等证据。
- 临床实践指南工作组与患者均将生存和纠正高钙血症列为治疗决策中最重要的结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Integrating shared decision making between patients and physicians and incorporating their values and preferences in the development of clinical practice guidelines (CPGs) is of critical importance to optimize CPG implementation and treatment adherence. This applies to many debilitating diseases, including hypercalcemia of malignancy (HCM). OBJECTIVE: Evaluate patient and physician values, preferences, and attitudes to better inform CPGs to treat HCM in adults. METHODS: We followed a mixed-methods approach. We conducted a systematic review using 5 databases to identify studies reporting on patient and physician values, costs and resources, feasibility, acceptability, and equity regarding HCM treatment. We also gathered data from different countries on the cost of multiple treatment modalities. We collected data on outcome prioritization from the CPG Working Group. Similarly, we collected data from patients with HCM regarding outcome prioritization and administered a questionnaire to evaluate their attitudes and perceptions toward treatment as well as treatment acceptability and feasibility. RESULTS: In the systematic review, we included 2 cross-sectional surveys conducted on the same population of physicians who agreed that treating HCM alleviates symptoms and improves quality of life; however, harms and benefits should be thoroughly considered when deciding on the duration of treatment. We also included 2 studies on cost showing that intravenous (IV) bisphosphonate is more cost-effective than a combination of IV bisphosphonate and calcitonin and administration of IV zoledronic acid at home is more cost-effective than other IV bisphosphonates. The cost of zoledronic acid, denosumab, and cinacalcet varied widely among countries and types (brand vs generic). Both the CPG Working Group and patients with HCM agreed that the most important outcomes when deciding on treatment were survival and resolution of HCM, but there was some variability in the ratings for other outcomes. CONCLUSION: Using mixed methods, CPG developers can obtain meaningful information regarding evidence to decision criteria. In the case of HCM CPGs, this approach has provided the required contextual information and supported the development of evidence-based recommendations.
引用
- Bassatne A, Murad MH, Piggott T, et al. Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study. J Clin Endocrinol Metab. 2023. PMID: 36545699. doi:10.1210/clinem/dgac630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。